Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.
Smith AL, Pal D, Martinez-Rico R, Eiken AP, Durden DL, Kutateladze TG, El-Gamal D. Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies. Leuk Lymphoma. 2023 Dec; 64(14):2333-2337.